Brochure
16 Sep 2024
Fempharma's portfolio
PDF 1.1 MB
The document introduces our product portfolio.
Content provided by our supplier
Fempharma
-
HU -
2021On CPHI since
-
1Certificates
-
1 - 24Employees
Company types
Other Content from Fempharma (1)
-
News Zinc containing vaginal gel shows promise as surprising emerging treatment for vaginal yeast infections.
Around three quarters of women develop vaginal yeast infections at least once in their lifetime, and approximately 140 million women globally suffer from recurrent infections. Recurrent yeast infections can have an enormous impact of quality of life. Existing anti-fungal treatments are not always effective and resistance against these treatments is developing. Vaginal yeast infection is caused by a yeast called Candida.
In a paper, published in Science Translational Medicine, we have shown that JUVIAGEL could be effective against recurrent yeast infections.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance